Ben Sullivan
Ben Sullivan covers clinical research and emerging diagnostics in health and medicine, with a focus on making complex trial data clear in everyday language. He writes about how new tests and treatments perform in rigorous studies, and what that performance means for patients, clinicians, and health systems.
Clinical trials and diagnostic performance
Sullivan reports repeatedly on studies that test how well new diagnostic tools work against standard care. In his coverage of urine-based screening for prostate cancer, he highlights a head-to-head trial showing that a urine test can cut unnecessary prostate biopsies by nearly two-thirds compared with MRI, grounding the story in trial design and quantitative outcomes.
He returns to similar ground in stories on blood and fluid biomarkers, screening strategies, and risk-stratification tools, emphasizing sensitivity, specificity, and comparative effectiveness rather than generic descriptions of innovation. His pieces typically walk through the study population, follow-up period, and key endpoints before turning to implications for clinical workflow and patient burden.
The emphasis is on what changes in practice — how many procedures might be avoided, how early disease can be detected, and which patients benefit or are missed — rather than on the technology alone. This gives his health reporting a practical, outcome-oriented bent that distinguishes it from more promotional coverage of new tests.
Neuroscience, cognition and brain-directed therapies
Sullivan frequently covers research at the intersection of neuroscience and clinical medicine. In his reporting on omega-3 fish oil supplements and Alzheimer’s disease, he explains that researchers have confirmed fish oil components do reach the brain, but that supplementation failed to slow cognitive decline, underscoring the gap between biological plausibility and clinical benefit.
He extends this approach to stories on nerve damage and spinal cord injury, where he follows work using human brain–spinal organoid models to study why mature neurons lose the ability to regenerate after axonal injury. He details how gene networks shift as neurons develop, and how targeting regulators like PTEN with contraceptive-derived compounds can reactivate growth machinery and increase axon regrowth.
Across these pieces, Sullivan focuses on mechanisms — developmental switches in regeneration, transcriptional states of neurons, transport of molecules across the blood–brain barrier — alongside the clinical endpoints of cognition, movement, and disability. He writes in plain English but preserves the causal chain from molecular biology to patient-level outcomes.
Plain-language science journalism and editorial role
Sullivan founded and edits Science Blog, a long-running online science outlet that publishes original science news reporting in plain English across health, brain and behavior, and other fields. He has spent more than two decades shaping the site’s approach to science communication, curating material from research organizations and working with science writers and editors.
In his own articles, he reflects that editorial philosophy by stripping away jargon where possible while retaining the key terms needed to understand trial results and biological mechanisms. Headlines and framing are direct, privileging the main finding — such as a therapy failing to improve clinical outcomes despite promising biological effects — over more speculative narratives.
His role combines writing and curation, so his health coverage often sits within a broader stream of stories that track how evidence accumulates across disease areas. That dual perspective gives his work an orientation toward the full research pipeline, from early mechanistic studies in organoids and connectoids to late-stage clinical trials and practice-changing diagnostics.
Health outcomes and patient impact
A thread running through Sullivan’s health reporting is concern with downstream impact on patients. When he covers new diagnostics, he quantifies reductions in invasive procedures and clarifies which patient groups stand to see fewer biopsies or scans. In neuroscience and neurodegenerative disease, he distinguishes between changes in biomarkers or imaging and tangible changes in memory, function, or mobility.
Rather than focusing on therapeutic hype, he gives equal weight to negative or null findings, such as supplements that alter brain chemistry but fail to change the trajectory of Alzheimer’s decline. This balance makes his coverage useful for readers who need a clear sense of what the evidence shows and where uncertainty remains, without overstating the promise of early-stage interventions.
4 more health journalists.
Abida Tasnim
Abida Tasnim is a health writer for The Daily Star who focuses on clear, practical guidance that helps readers recognise risks early and act before everyday illnesses turn into wider public health problems. She reports on infectious disease prevention, using measles coverage to show how outbreaks start with individual decisions and behaviours, not just hospital statistics. Her work explains what happens during an outbreak and then anchors the story in simple steps people can take, such as avoiding crowded places when symptoms appear, practising good hygiene, and seeking medical advice early. She writes direct, action‑oriented health explainers that turn clinical questions about contagion and disease burden into everyday choices. Across her beat, she stresses early recognition, timely care, and prevention as the foundations of healthier communities.
Adrián Carballo Casla
Adrián Carballo Casla stands out for turning complex cohort data on ageing into clear, food‑level advice on what older adults should eat to protect brain health and slow chronic disease. He is a researcher in nutritional epidemiology focused on ageing and chronic disease prevention and a postdoctoral researcher in geriatric epidemiology at Karolinska Institutet, writing health explainers for The Conversation. He reports on how diet quality, especially Mediterranean and Mind‑style patterns, shapes dementia risk, grey matter loss and neurocognitive ageing, and how healthy versus pro‑inflammatory diets alter multimorbidity trajectories. His articles translate findings on flavonoids, polyphenols, folate, omega‑3 fats and dietary nitrates into specific food choices and small, practical changes. Much of his coverage is anchored in his own studies on multimorbidity, high‑risk older adults and tailored dietary recommendations, often syndicated to other outlets.
Ahmed Elbediwy
Ahmed Elbediwy brings a lab-based understanding of cancer biology and clinical biochemistry to public-facing health reporting, linking drug mechanisms and molecular pathways to everyday choices about medicines and products. He writes for The Conversation on weight-loss injections, cancer overdiagnosis and anti-ageing supplements, focusing on obesity medicine, cancer signalling, screening trade-offs, skincare and supplement science. His pieces on GLP-1 drugs such as Ozempic, Wegovy and Mounjaro explain why some people do not respond, how gut hormones and appetite signals work, and where psychological support and nutrition fit alongside prescriptions. He co-authors explainers on cancer risk and overdiagnosis and on whether supplements can reverse ageing, separating established knowledge from emerging research. An award-winning senior lecturer at Kingston University, he favours clear, structured explainers, careful definition of key terms and evidence-based appraisal over hype.
Amanda Sheppeard
Amanda Sheppeard is a managing editor and health journalist known for long, detailed explainers that connect complex clinical research, disability policy and political narratives with the daily realities of doctors and patients. She works at The Medical Republic across editorial leadership and commercial content while reporting widely on medicine for its specialist titles. Her real beat spans autism, disability policy, autoimmune disease, infectious threats and system pressures in primary care and hospitals. She covers subjects such as autism diagnosis and the NDIS, rheumatology’s clinical shifts, weight-loss agents in rheumatoid arthritis, infection control, antimicrobial resistance and new modalities like CAR T-cell therapy and microneedles. She reports by doing the synthesis inside the story, linking trial design, molecular targets, funding rules and policy changes to concrete decisions and workflows in clinics and hospitals.